P1.07.43 Clinico-Genomic Correlates of Pathologic Response to Neoadjuvant Chemo-Immunotherapy in Patients With Early-Stage NSCLC
Edoardo Garbo(Dana-Farber Cancer Institute), B. Ricciuti(Dana-Farber Cancer Institute), Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center), M.M. Awad(Memorial Sloan Kettering Cancer Center), Igor Odintsov(Brigham and Women's Hospital), L.M. Sholl(Brigham and Women's Hospital), J. Chaft(Memorial Sloan Kettering Cancer Center), Grace M. Hambelton(Massachusetts General Hospital), Adnan Aijaz(Toshiba (United Kingdom)), M. Aldea(Dana-Farber Cancer Institute), Valentina Santo(Dana-Farber Cancer Institute), F. Cappuzzo(National Cancer Institute), L. Zullo(Institut Gustave Roussy), Jordi Remón(Vall d'Hebron Hospital Universitari), David A. Barbie(Dana-Farber Cancer Institute), Alessandro Di Federico(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Sonal Pannu(Oklahoma City University), Justin F. Gainor(Harvard University), F. Fusco(National Cancer Institute), Abdul Rafeh Naqash(Oklahoma City University), Eleonora Gariazzo(Dana-Farber Cancer Institute), Federica Pecci(University of Parma), A. Cooper(Memorial Sloan Kettering Cancer Center), X. Wang(Harvard University)
Cited by 0
Related Papers
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
|Cell|2018|2k
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
|Cell|2018|1.5k
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
|Clinical Cancer Research|2016|1.2k
Acquired Resistance to Immune Checkpoint Inhibitors
|Cancer Cell|2020|927